Centaur Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Centaur Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $11.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Centaur Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $11.1M Trade | TransData Nexus

Centaur Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $11.1M Total Trade · DGFT Verified

Centaur Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $11.1M across 6 products in 4 therapeutic categories. Based on 333 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metformin ($7.1M), Gliclazide ($1.8M), Clonazepam ($714.2K).

Centaur Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Centaur Pharmaceuticals Private Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Centaur Pharmaceuticals Private Limited? — Company Overview & Market Position

Centaur Pharmaceuticals Private Limited, established on October 15, 1980, is a privately held Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24230MH1980PTC023291. As of the latest available data, Centaur Pharmaceuticals has an authorized share capital of ₹200 million and a paid-up capital of ₹184.96 million. The company employs approximately 2,700 individuals, reflecting its significant presence in the pharmaceutical industry. Centaur Pharmaceuticals operates across various segments, including Active Pharmaceutical Ingredients (API), formulations, Contract Research and Manufacturing Services (CRAMS), Clinical Research, Research and Development (R&D), regulatory affairs, and marketing.

What Does Centaur Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$7.1M 2Gliclazide$1.8M

Product Portfolio — Top 6 by Export Value

Centaur Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$7.1M	173	1.5%	13
2	Gliclazide	Advanced Diabetes Medications	$1.8M	36	0.6%	12
3	Clonazepam	CNS & Psychiatric	$714.2K	24	0.6%	5
4	Alprazolam	CNS & Psychiatric	$620.9K	29	3.7%	7
5	Lorazepam	CNS & Psychiatric	$552.8K	34	18.8%	2
6	Tetracycline	Antibiotics	$311.5K	37	1.8%	11

Centaur Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $11.1M. The top category is Diabetes & Endocrine (63.9% of portfolio), followed by CNS & Psychiatric (17.0%), indicating a concentrated portfolio with the top 5 products accounting for 97.2% of total export value.

Centaur Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Centaur Pharmaceuticals operates multiple manufacturing facilities to cater to diverse market needs. The Goa facility, approved by the U.S. Food and Drug Administration (FDA), specializes in the production of Sinarest, India's leading anti-cold medication. This facility has been recognized for its marketing excellence, winning the 'Brand of the Year for Marketing Excellence' seven times consecutively. Additionally, Centaur has a fully scalable 25,000-square-meter finished dosage formulations facility in Pune, designed to serve international markets. This facility boasts an annual capacity of 3 billion tablets and 600 million capsules, housing both formulations R&D and analytical development sections.

3Key Leadership

The leadership team at Centaur Pharmaceuticals includes:

Shivanand Dattatraya Sawant: Managing Director since October 15, 1980.

Sharadchandra Damodar Abhyankar: Director since August 11, 2016.

Albert Taura: Director since August 11, 2016.

Smita Abhayakumar Phal: Whole-Time Director since June 22, 2011.

Rakhi Shridhar Kadam: Whole-Time Director since September 14, 2015.

Supriya Samar Desai: Whole-Time Director since December 21, 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Centaur Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Centaur Pharmaceuticals has established a presence in several regulated markets, including the United States, Europe, the United Kingdom, Australia, and Japan. The Goa facility's approval by the U.S. FDA underscores the company's commitment to meeting stringent international standards. However, in June 2023, the FDA issued a warning letter to Centaur Pharmaceuticals, citing deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API) at their Ambernath facility. The letter highlighted issues such as inadequate document control and failure of the quality unit to ensure compliance with CGMP. This incident may impact the company's standing in other regulated markets, necessitating prompt corrective actions to maintain market access.

2Emerging Markets

Centaur Pharmaceuticals has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's portfolio includes 57 APIs, with 38 being pioneered for the first time in India, indicating a strong focus on innovation. Additionally, Centaur has developed a new chemical entity, Woxheal, for the treatment of diabetic foot ulcers, demonstrating its commitment to addressing unmet medical needs. While the company has not explicitly stated WHO prequalification for its products, its active engagement in these regions suggests a strategic approach to penetrating emerging markets.

Centaur Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Centaur Pharmaceuticals' manufacturing facilities are registered with the FDA, indicating compliance with U.S. regulations. However, the June 2023 warning letter from the FDA highlights significant deviations from CGMP at their Ambernath facility, including inadequate document control and failure of the quality unit to ensure compliance with CGMP. This incident underscores the importance of stringent quality control measures and may impact the company's ability to maintain or expand its market presence in the U.S.

2WHO & EU GMP

Centaur Pharmaceuticals' Goa facility is approved by the U.S. FDA, indicating adherence to international manufacturing standards. The company also holds WHO-GMP certifications for its formulations facilities in Goa, catering to both Indian and international markets. However, there is no explicit information available regarding EU GMP certifications or EDQM status. This lack of certification may limit the company's ability to access certain European markets and could be a consideration for potential partners and customers.

3CDSCO & Indian Regulatory

Centaur Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Centaur Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on APIs, formulations, and contract manufacturing services positions it alongside other Indian pharmaceutical firms with similar capabilities. However, the recent FDA warning letter may affect Centaur's competitive standing, especially in markets where regulatory compliance is critical. The company's strong presence in emerging markets may provide a competitive edge, but it also faces competition from both local and international companies targeting these regions.

2Key Differentiators

Centaur Pharmaceuticals differentiates itself through its fully integrated operations across the pharmaceutical value chain, including API manufacturing, formulations, clinical research, and contract manufacturing services. The company's focus on innovation is evident in the development of Woxheal, a new chemical entity for the treatment of diabetic foot ulcers. Additionally, Centaur's strong presence in emerging markets and its ability to cater to both domestic and international markets through WHO-GMP approved facilities are notable strengths.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Centaur Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Centaur Pharmaceuticals has a diverse supplier base, supporting its operations across API manufacturing, formulations, and contract manufacturing services. The company's export volume of $11.1 million USD across 333 shipments indicates a consistent track record in international trade.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Centaur Pharmaceuticals Private Limited

How many pharmaceutical products does Centaur Pharmaceuticals Private Limited export from India?

Centaur Pharmaceuticals Private Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Metformin ($7.1M), Gliclazide ($1.8M), Clonazepam ($714.2K), Alprazolam ($620.9K), Lorazepam ($552.8K). Total export value is $11.1M.

What is Centaur Pharmaceuticals Private Limited's total pharmaceutical export value?

Centaur Pharmaceuticals Private Limited's total pharmaceutical export value is $11.1M, based on 333 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Centaur Pharmaceuticals Private Limited cover?

Centaur Pharmaceuticals Private Limited exports across 4 therapeutic categories. The largest are Diabetes & Endocrine (63.9%, 1 products), CNS & Psychiatric (17.0%, 3 products), Advanced Diabetes Medications (16.2%, 1 products).

Get Full Centaur Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.